launched July 1, 2026 through December 31, 2027 Who Faces the Greatest Need for This Coverage The groups most likely to benefit from the Medicare GLP-1 Bridge program include: Medicare Part D enrollees ages 65 and older with a body mass index of 35 or higher, or a BMI of 27 or higher combined with a qualifying condition such as cardiovascular disease or prediabetes Adults with obesity who were previously unable to afford brand-name GLP-1 medications on fixed retirement incomes People who discontinued brand-name GLP-1 treatment due to cost and are eligible to re-enter with the $50 Bridge copay Patients managing obesity-related conditions including hypertension, sleep apnea, and prediabetes, who may reduce downstream healthcare costs through weight management People who already receive GLP-1 coverage through their Part D plan for diabetes, cardiovascular disease, or sleep apnea do not qualify for the Bridge program they continue to access the drugs through their existing coverage
They may have some questions for you
The woman, who lives in Louisiana, lost around 150 pounds on the two medications, according to her attorney, Paul Pennock, a New York City-based attorney for Morgan & Morgan, According to the lawsuit, the woman, who has not been officially diagnosed with gastroparesis, suffered "severe gastrointestinal events," including, "severe vomiting, stomach pain, [and] gastrointestinal burning." "Her problems have been so severe that she's been to the emergency room multiple times, including last week," Pennock told ABC News Wednesday
Arkofluido LipoPIC GLP-1 270 grams + Bottle 30-Day Program is a powdered food supplement designed as a complete 30-day weight management program
Avoid Alcohol: Alcohol can worsen dizziness, impair judgment, and may interfere with both phentermines effectiveness and your weight loss progress
Semaglutide is a GLP-1 receptor agonist that mimics the incretin hormone your body naturally produces after eating
